Lack of an association of GNB3 C825T polymorphism and blood pressure in patients with rheumatoid arthritis

Clinical and Experimental Hypertension

Volumn 31, Issue 5, 2009, Pages 428-439

  Panoulas, Vasileios F ^a,b   Smith, Jacqueline P ^a   Stavropoulos Kalinoglou, Antonios ^a   Douglas, Karen M J ^a   Nightingale, Peter ^c   Kitas, George D ^a,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Blood pressure; Cardiovascular disease; GNB3 gene; Hypertension; Polymorphism; Rheumatoid arthritis; Rs5443

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN BETA 3 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PHENOTYPE; PREVALENCE; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

AGED; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CASE-CONTROL STUDIES; ENDOTHELIN-1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70849113534     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802668748     Document Type: Article

References (47)

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Rheumatology 2002; 41:793-800.
2. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30:36-40.
3. Dessein PH, Joffe BI. When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 2006; 33:201-203.
4. Panoulas VF, Milionis HJ, Douglas KM, Nightingale P, Kita MD, Klocke R, Elisaf MS, Kitas GD. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:1466-1470.
5. Panoulas VF, Nikas SN, Smith JP, Douglas KM, Nightingale P, Milionis HJ, Treharne GJ, Toms TE, Kita MD, Kitas GD. The Lymphotoxin 252A > G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2008; doi:10.1136/ard.2007.082594.
6. Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2004; 33:293-299. (Pubitemid 39421211)
7. Criswell LA, Merlino LA, Cerhan JR, Mikuls TR, Mudano AS, Burma M, Folsom AR, Saag KG. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: Results from the Iowa Women's Health Study. Am J Med 2002; 112:465-471. (Pubitemid 34450707)
8. Situnayake RD, Kitas G. Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 1997; 56:341-342.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-952.
10. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:1477-1482.
11. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebocontrolled trial. Lancet 2004; 363:2015-2021.
12. Panoulas VF, Douglas KM, Milionis HJ, Nightingale P, Kita MD, Klocke R, Metsios GS, Stavropoulos-Kalinoglou A, Elisaf MS, Kitas GD. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens 2008; 22:177-182.
13. Tanira MO, Al Balushi KA. Genetic variations related to hypertension: A review. J Hum Hypertens 2005; 19:7-19.
14. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N, Hartung K, Beckmann S, Jakobs KH. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 1995; 96:759-766.
15. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005;56:17-28.
16. Wenzel RR, Siffert W, Bruck H, Philipp T, Schafers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics 2002; 12:489-495.
17. Gonzalez-Juanatey C, Gonzalez-Gay MA. Long-term rheumatoid arthritis and endothelial dysfunction. Atherosclerosis 2004; 176:197-198.
18. Pache M, Schwarz HA, Kaiser HJ, Wuest P, Kloti M, Dubler B, Flammer J. Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 2002; 8:CR616-CR619.
19. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 2006; 25:314-319.
20. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
21. Klocke R, Cockcroft JR, Taylor GJ, Hall IR, Blake DR. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003; 62:414-418.
22. Arosio E, De Marchi S, Rigoni A, Prior M, Delva P, Lechi A. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 2007; 25:1273-1278.
23. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46:194-199.
24. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63:1085-1089.
25. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51:1029-1035.
26. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-48.
27. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986, 25:206-209.
28. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, McColl G, Best J, Jenkins A. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48:81-89.
29. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:72-75.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
31. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake RD, Gordon C, Salmon M, Kitas GD. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32:231-238.
32. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25:206-209.
33. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG TS. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-185.
34. National Collaborating Centre for Chronic Conditions.. Hypertension: Management of hypertension in adults in primary care: Partial update. London: Royal College of Physicians, 2006.
35. Automated nucleic acid exraction-QuickGene-810. http://www.autogen.com/ Products/Quick Gene810.htm. Last accessed January 6, 2008.
36. LightCycler 2.0 System http://www.roche-applied-science.com/sis/rtpcr/ lightcycler/index.jsp. Last accessed January 6, 2008.
37. Bagos PG, Elefsinioti AL, Nikolopoulos GK, Hamodrakas SJ. The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls. J Hypertens 2007; 25:487-500.
38. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R634-R643.
39. Gonzalez-Gay MA, Gonzalez-Juanatey C, Ollier WE. Endothelial dysfunction in rheumatoid arthritis: Influence of HLA-DRB1 alleles. Autoimmun Rev 2004; 3:301-304. (Pubitemid 38898665)
40. Epidemiology and Public Health at the Royal Free and University College Medical School. Commissioned by Department of Health. Health survey for England 2003. Department of Health, 2004.
41. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340:1012-1020.
42. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-48.
43. Zeltner R, Delles C, Schneider M, Siffert W, Schmieder RE. G-protein beta(3) subunit gene (GNB3) 825T allele is associated with enhanced renal perfusion in early hypertension. Hypertension 2001; 37:882-886.
44. Rosskopf D, Busch S, Manthey I, Siffert W. G protein beta 3 gene: Structure, promoter, and additional polymorphisms. Hypertension 2000; 36:33-41.
45. LaMorte VJ, Harootunian AT, Spiegel AM, Tsien RY, Feramisco JR. Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2. J Cell Biol 1993; 121:91-99.
46. Goodson NJ, Silman AJ, Pattison DJ, Lunt M, Bunn D, Luben R, Day N, Khaw KT, Symmons DPM. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology 2004; 43:731-736.
47. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-743.